



Advanced Therapies

- October 2023 -

Advanced Therapies Funding - October 2023 By Amount Raised (1 of 2)

The category includes Cell, Gene, mRNA and Microbiome Therapies.

Advanced Therapies accounted for **\$215.8 Million** of Deals (4.5% of total), Across **13** Deals

Date	Company	Investment Cluster	Modality	About	Investment (\$M)	Round	Investors
10-24	Rampart Bioscience	San Diego	Gene Therapy	Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.	\$85.00	Series A	Forbion leads with participation from OrbiMed, RA Capital Management and HealthCap
10-19	DermBiont	Boston	Microbiome	DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases.	\$35.20	Series B	Viking Global, Olive Tree Capital, Double Point Ventures, Civilization Ventures
10-30	MeiraGTx	New York	Gene Therapy	MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.	\$30.00	Post IPO Equity	Sanofi
10-20	Interius BioTherapeutics	Philadelphia	Cell Therapy	Interius BioTherapeutics is a biopharmaceutical company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.	\$21.50	Debt	
10-13	Gritstone Bio	San Francisco	mRna	Gritstone Bio won \$10 million for its self-amplifying mRNA-based vaccine	\$10.00	Grant	BARDA Project NextGen

Advanced Therapies Funding - October 2023 By Amount Raised (2 of 2)

Date	Company	Investment Cluster	Modality	About	Investment (\$M)	Round	Investors
10-04	Swan Bio Therapeutics	Philadelphia	Gene Therapy	SwanBio Therapeutics is a gene therapy company focused on the development and commercialisation of genetically defined therapies.	\$10.00	Venture	Syncona Investment Management
10-19	mybacs	Europe	Microbiome	mybacs is a Biotechnology company specialized in the human microbiome.	\$5.90	Series A	WENVEST Capital, SevenVentures, naturalX Health Ventures, Joyance Partners, Global Founders Capital,, G-Fund
10-27	Ray Therapeutics, Inc.	San Francisco	Gene Therapy	RayTx is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and will not require light-enhancing goggles).	\$4.62	Grant	CRIM
10-26	Mustang Bio	Boston	Gene Therapy	Mustang Bio is a clinical-stage biopharmaceutical company .	\$4.40	Post IPO Equity	
10-12	Longeveron Inc	Miami	Cell Therapy	Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.	\$4.00	Post IPO Equity	
10-27	Siren Biotechnology, Inc.	San Francisco	Gene Therapy	At Siren, we are combining the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single, powerful new treatment modality to fight cancer.	\$3.99	Grant	CRIM
10-30	Laverock Therapeutics	Europe - UK	Cell Therapy	Gene silencing platform for the creation of programmable, allogeneic cell therapies.	\$1.20	Grant	UK Innovation